Carbohydrate (i.e., Saccharide Radical Containing) Doai Patents (Class 514/23)
  • Patent number: 11369664
    Abstract: The present disclosure is concerned with compositions comprising insulin and a pharmaceutically acceptable topical carrier. The present disclosure is also concerned with methods of using these compositions for the treatment of a skin ailment such as a diabetic ulcer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: June 28, 2022
    Assignee: Eleos Pharmaceuticals, Inc.
    Inventors: Mona E. Buice, David M. Sailors, Joshua Z. Greeson
  • Patent number: 11340226
    Abstract: The present invention provides a method for providing a diagnosis or prognosis of a non-alcoholic fatty liver disease (NAFLD) in a subject by detecting expression level of the Squalene Epoxidase (SQLE) gene. A kit and device useful for such methods are also provided. In addition, the present invention provides a method for treating NAFLD by suppressing SQLE gene expression or activity.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: May 24, 2022
    Assignee: The Chinese University of Hong Kong
    Inventors: Jun Yu, Dabin Liu, Chi-Chun Wong
  • Patent number: 11338023
    Abstract: There is provided a composition including parietal polysaccharides from at least one Candida species and parietal polysaccharides from at least one different yeast species. The composition can be used in modulating and/or stimulating immune responses in animal or human.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: May 24, 2022
    Assignee: DANSTAR FERMENT AG
    Inventor: Mathieu Castex
  • Patent number: 11311556
    Abstract: The invention features topical dutasteride emulsions for local delivery to the dermis of a subject suffering from hair loss, such as hair loss secondary to endocrine therapy in patients with breast cancer.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: April 26, 2022
    Assignee: Varsona Therapeutics, Inc.
    Inventors: Vinay Kumar Jindal, Manu Gujrati, Mary Angelica Oba Magsombol-Karaan
  • Patent number: 11304966
    Abstract: The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human. The human is administered a composition comprising 6?-sialyllactose (6?-SL) and/or lacto-N-tetraose (LNT).
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 19, 2022
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs, Sami Damak, Norbert Sprenger, Francis Foata
  • Patent number: 11278557
    Abstract: The invention belongs to the field of biomedicine, and particularly relates to a glucose core, comprising a glucose and/or a glucose hydrate, a diluent and a binder, wherein, the glucose and/or the glucose hydrate is present in the glucose core in an amount of ?85% by weight percentage; and relates to a glucose pellet comprising the glucose core and a laminated layer coating the glucose core; and further relates to a pharmaceutical composition comprising the glucose pellet. The glucose pellet or the pharmaceutical composition of the invention are useful in treatment and/or assistant treatment of a glycogen storage disease and/or a diabetes.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: March 22, 2022
    Assignee: COSCI MED-TECH CO. LTD.
    Inventors: Changqing Zhang, Dezhi Zhu, Shenghai Zhang, Jie Ning, Xiaoyan Xian
  • Patent number: 11260032
    Abstract: A nano drug delivery system includes a biofilm-coated drug nanocrystal. A drug in a physical form of nanocrystal is directly used as a rigid supporting skeleton, and is filled in a biofilm. The nano drug delivery system has the advantages of high drug loading capacity, good biocompatibility, long systemic circulation time and drug sustained release.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 1, 2022
    Assignee: Shanghai Whittlong Pharmaceutical Institute
    Inventors: Weiyue Lu, Zhilan Chai, Xuefeng Hu, Cao Xie, Huimin Hou, Hao Wang
  • Patent number: 11260096
    Abstract: Disclosed herein are methods for creatine supplementation for human subjects, particularly creatine non-responders.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: March 1, 2022
    Assignee: ThermoLife International, LLC
    Inventors: Ronald Kramer, Alexandros Nikolaidis
  • Patent number: 11241420
    Abstract: The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPAR?) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPAR? agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: February 8, 2022
    Assignee: Omeros Corporation
    Inventor: Roberto Ciccocioppo
  • Patent number: 11225500
    Abstract: The invention relates to a process for the manufacture of the crystalline compound according to formula (I) comprising the steps (a) deacetylating the final intermediate (FI), (b) forming the crystalline compound according to formula (I) by reacting the deacetylated final intermediate of step (a) with L-proline and water and isolating the final reaction product; processes of manufacturing intermediates thereof; process intermediates and their uses in the processes according to the present invention.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: January 18, 2022
    Inventors: Matthias Eckhardt, Monika Brink, Frank Himmelsbach, Stefan Sahli, Chutian Shu, Xiao-Jun Wang, Beat Theodor Weber, Bing-Shiou Yang
  • Patent number: 11220516
    Abstract: The present disclosure provides for modified antibiotic compounds, methods of making modified antibiotic compounds, methods of use, products including modified antibiotic compounds, and the like. The modified antibiotic compound comprises a nitric oxide release agent covalently attached to an antibiotic molecule, such as S-nitroso-N-acetylpenicillamine covalently attached to ampicillin.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: January 11, 2022
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Hitesh Handa, Sean P. Hopkins, Priyadarshini Singha, Christina Danielle Workman
  • Patent number: 11202798
    Abstract: The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: December 21, 2021
    Assignee: REVEN PHARMACEUTICALS, INC.
    Inventors: Peter Lange, Brian Denomme, Henk Van Wyk, Mariette Van Wyk, Tracy L. Krebs, Sezgin Ozgur, Zishan Haroon
  • Patent number: 11191835
    Abstract: The present disclosure relates to novel chlorin-vitamin conjugates and method of making and using the chlorin-vitamin conjugates.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: December 7, 2021
    Assignee: Purdue Research Foundation
    Inventor: Meden Fruel Isaac-Lam
  • Patent number: 11179364
    Abstract: The disclosure concerns the use of LIK066 in the treatment, prevention or delay of non-alcoholic steatohepatitis.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: November 23, 2021
    Assignee: Novartis AG
    Inventors: Lloyd Klickstein, C. Daniel Meyers, Chinweike Ukomadu
  • Patent number: 11180788
    Abstract: The present invention discloses a method for preparing lower graft degree GSGs, and belongs to the technical field of biosynthesis of sweeteners. The method uses amylase to catalyze hydrolysis of GSGs with a high graft degree, thereby obtaining GSGs with low graft degree mainly containing GSGs with a low grafting number. The content of mono- and di-glucosyl substituents in the SGs in the product was 60% or more of the total glycosides, and the mass percent of the GSGs with a glucosyl grafting number of 3 or less was higher than 70% of the total glycosides. The mono- and di-substituted GSGs obtained by enzyme catalysis by the present invention were structurally similar to those, belong to a mixture of the isomers thereof, and have good sweetness and a flavoring function.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: November 23, 2021
    Assignees: Jiangnan University, Dongtai Haorui Biotechnology Co., Ltd.
    Inventors: Yongmei Xia, Liping Zhu, Tongtong Zhang, Guoying Du, Xiang Liu, Yun Fang
  • Patent number: 11141450
    Abstract: A method for enhancing at least one of craving-reduction, mood improvement, avoidance of depression, prevention of weight gain post weight-loss from dieting, reduction of negative side effects produced by anti-appetite drugs and smoke-cessation and promotion of healthy ageing in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b). The composition may comprise a third active ingredient in combination with the Cyperus esculentus extract and mangiferin or norathyriol.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: October 12, 2021
    Assignee: NEKTIUM PHARMA, S.L.
    Inventors: Miguel Jiménez del Río, Julia C. Wiebe, Laura López-Ríos, Tanausú Vega Morales, Rubén Peréz Machín, Alvaro Sánchez Rodríguez, Carlos J. Mateos, Nigel Peter Gericke
  • Patent number: 11129401
    Abstract: Provided herein is a method of improving the taste profile of a glucosylated terpene glycoside (GTG) comprising: a) mixing a malted cereal with a glucosylated terpene glycosides in water to form a GTG cereal mixture wherein the cereal comprises an amylase; b) adjusting the temperature of the mixture to a temperature sufficient to activate the amylase and for a time sufficient to form a mixture comprising glycosylated steviol glycosides wherein the average number of glucose units of the GTG in the GTG cereal mixture is reduced.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: September 28, 2021
    Assignee: Firmenich SA
    Inventors: Wen-Juan Xiang, Dan-Ting Yin, Olivier Haefliger
  • Patent number: 11102994
    Abstract: Provided herein are beverage compositions to be ingested by a patient prior to administration of anesthesia or sedation comprising: a) one or more carbohydrates, wherein the total Calories available from the carbohydrates is at least about 200 and wherein the one or more carbohydrates are the sole source of significant Calories in the beverage; b) an acid, in a quantity sufficient to result in a pH of at least about 3.7 to about 4.5 and to enhance the shelf life and flavor of the beverage; c) a central nervous system (CNS) stimulant that is also a cerebro-vasoconstrictor; d) a sweetener and e) water, wherein the beverage composition, when ingested at least about two hours prior to administration of anesthesia or sedation is effective to relieve one or more symptoms associated with prolonged fasting. Further provided herein are methods of using the pre-operative beverage compositions disclosed herein in preparation for the safe induction of anesthesia or sedation in a patient before surgery.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: August 31, 2021
    Assignee: CLEARFAST INC.
    Inventor: M. Lou Marsh
  • Patent number: 11103433
    Abstract: Compositions comprising one or more chelating agents and optionally zinc ion salts are used to inhibit the growth or biofilm formation in bacteria associated with personal care products such as ophthalmic, pedicure, manicure or podiatric solutions. The compositions of the present application can also comprise gelling agents, antimicrobials, antibiotic or a pH adjuster. The compositions may be in the form of a solution, a gel, a cream, a jelly, a powder, a paste, a lotion, soap and a cleaner.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: August 31, 2021
    Assignee: KANE BIOTECH INC.
    Inventors: Purushottam V. Gawande, Karen Lovetri, Nandadeva Yakandawala, Gord Froehlich, Srinivasa Madhyastha
  • Patent number: 11090287
    Abstract: A pharmaceutical composition or dietary supplement with antioxidant activity, mood-regulating activity and insulin-sensitizing activity, with a consequent reduction of the accumulation of adipose tissue, is described, for use in the prevention and treatment of metabolic disorders associated with menopause and climacteric. The composition of the invention comprises, as active ingredients, a combination of alpha-lipoic acid, curcumin and L-tryptophan.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: August 17, 2021
    Assignee: Kolinpharma S.p.A.
    Inventors: Domenico Bijno, Carmine Di Vincenzo, Emanuele Lusenti, Alberto Martina, Ritapaola Petrelli
  • Patent number: 11090323
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: August 17, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, Hans-Juergen Woerle
  • Patent number: 11084842
    Abstract: A glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: August 10, 2021
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng Gu, Wuyong Wu, Tong Qu, Panpan Kang, Zongyuan Zhang, Weiming Huang, Jianyu Liu, Yingjun Zhang
  • Patent number: 11077078
    Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: August 3, 2021
    Assignee: KoDiscovery, LLC
    Inventor: Young Hee Ko
  • Patent number: 11040050
    Abstract: This invention relates generally to compositions and methods for preventing or treating mast cell mediated visceral pain.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 22, 2021
    Assignee: Glycom A/S
    Inventors: Louise Kristine Vigsnæs, Bruce McConnell, Emma Elison
  • Patent number: 11040049
    Abstract: The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: June 22, 2021
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
  • Patent number: 11026959
    Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient a mixture comprising 2?-fucosyllactose (2?-FL) and lacto-N-neotetraose (LNnT).
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 8, 2021
    Assignee: Glycom A/S
    Inventors: Thierry Hennet, Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
  • Patent number: 11020351
    Abstract: The invention relates to stable bilayer tablet compositions comprising empagliflozin, linagliptin and pharmaceutically acceptable excipients which show no incompatibilities and the compositions having good stability and superior dissolution profile.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: June 1, 2021
    Assignee: HETERO LABS LIMITED
    Inventors: Parthasaradhi Reddy Bandi, Khadgapathi Podile, Sunil Deviprasad Tiwari, Srinivasa Rao Gella
  • Patent number: 11020412
    Abstract: The present invention relates to solid oral pharmaceutical compositions comprising amorphous dapagliflozin. The invention further relates to a process for the preparation of the said pharmaceutical compositions. The said compositions are administered orally for the treatment of diabetes mellitus. The said compositions provide the desired immediate release of dapagliflozin and were found to be stable under accelerated conditions.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 1, 2021
    Assignee: INVENTIA HEALTHCARE LIMITED
    Inventors: Vaibhavi Shah, Vijayendrakumar Redasani, Anant Ghongade
  • Patent number: 11020447
    Abstract: Disclosed herein are methods for treating type II diabetes mellitus. In particular, the present invention relates to methods of using an extract of Hedychium coronarium Koenig and a blood glucose reduction agent, to synergistically reduce the blood glucose level of the subject having type II diabetes mellitus.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: June 1, 2021
    Assignee: VITNOVO, INC.
    Inventors: Pei-Ran Wang, Rey-Yuh Wu, Yu-Yuan Wu, Lung-Yu Kuan, Klim King
  • Patent number: 11007172
    Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: May 18, 2021
    Assignees: NIIGATA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Tohru Minamino
  • Patent number: 10987338
    Abstract: The present disclosure provides a composition of artesunate, a process of preparing the same, and a method of treatment.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: April 27, 2021
    Inventors: Ming Zhao, Li-Ming Zhou
  • Patent number: 10980822
    Abstract: Provided is a pharmaceutical composition comprising an antidiabetic agent and an antihypertensive agent as active ingredients.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: April 20, 2021
    Assignee: AUTOTELIC BIO INC.
    Inventor: Tae-Hun Kim
  • Patent number: 10976322
    Abstract: A galactose oral composition having galactose, an antioxidant and a buffer. The galactose oral composition contains 1%-80% by weight of galactose. The antioxidant is selected from Vitamin A, Vitamin C, Vitamin E, Ethylenediaminetetraacetic acid (EDTA), sodium bisulfite, flavonoids, polyphenols, Diethylenetriaminepentaacetic acid (DTPA), and NTA-Nitrilotriacetate acid (NTA). The buffer is selected from ascorbic acid buffer, citrate buffer, phosphate buffer, acetate buffer, carbonate buffer, and triethanolamine buffer. The galactose oral composition can be applied to detect individual galactose metabolic ability to assess liver function.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: April 13, 2021
    Assignee: AVALON HEPAPOC LIMITED
    Inventors: Oliver Yoa-Pu Hu, Ping Yang, Cheng-Huei Hsiong
  • Patent number: 10952989
    Abstract: The present invention is drawn to methods for effecting weight loss, e.g. in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 23, 2021
    Assignee: Novartis AG
    Inventors: Deborah Lynn Keefe, Qing Shao
  • Patent number: 10945975
    Abstract: Provided herein are compositions and methods for preventing central nervous system oxygen toxicity in a subject.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: March 16, 2021
    Assignee: University of South Florida
    Inventors: Csilla Ari D'Agostino, Dominic Paul D'Agostino, Jay B. Dean
  • Patent number: 10889609
    Abstract: The present invention relates to a mannitol-based amphipathic compound, a method of preparing the same, a method of extracting, solubilizing, stabilizing or crystallizing a membrane protein using the compound, and a method of analyzing a structure of the membrane protein under an electron microscope using the compound. When the mannitol-based compound according to the present invention is used, the membrane protein can be stably stored in an aqueous solution for a prolonged period of time and thus can be applied to analysis of functions and structures thereof. Since the analysis of the structures and functions of the membrane protein is one of the fields of most interest in biology and chemistry currently, and more than half of new drugs currently in development are targeting membrane proteins, the present invention is applicable to research on the structures of membrane proteins closely related to the development of the new drugs.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 12, 2021
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
    Inventors: Pil Seok Chae, Hazrat Hussain
  • Patent number: 10864224
    Abstract: The invention relates to a synthetic composition comprising human milk oligosaccharides for use in at least partially restoring the commensal gastrointestinal microbiota and preventing or mitigating antibiotic associated diarrhoea.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: December 15, 2020
    Assignee: GLYCOM A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs, David Paul Kronlage
  • Patent number: 10857168
    Abstract: This invention relates to a method and composition for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: December 8, 2020
    Assignee: GLYCOM A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs
  • Patent number: 10851367
    Abstract: The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: December 1, 2020
    Assignees: Pfizer Inc., The Regents of the University of California
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Aaron Thuma, Jennifer A. Doudna, Romain Rouet
  • Patent number: 10836786
    Abstract: Disclosed are a crystal form of a dapagliflozin intermediate and a preparation method therefor, and specifically disclosed are a crystal form of the dapagliflozin intermediate (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyOphenyl)-2-ethoxy-6-(methylhydroxyl) tetrahydro-2H-pyran-3,4,5-triol and a preparation method therefor. The advantages thereof lie in that an intermediate can be highly purified to obtain a sample with a purity of 99.3% or more, which has an important significance for improving the quality of the dapagliflozin, and the preparation process is simple and suitable for industrial production.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: November 17, 2020
    Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Inventors: Xiang Li, Jun Yu, Haizhou Yu, Jinjia Wang, Lei He, Zuyin Du
  • Patent number: 10829509
    Abstract: Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: November 10, 2020
    Assignee: OPKO Pharmaceuticals, LLC
    Inventors: Tahir Ahmed, Arie Gutman, Irina Fedotev, Igor Rukhman, Olga Grossman
  • Patent number: 10800811
    Abstract: Object of the invention is a synthetic peptide, in particular a synthetic peptide to be used as medicament, in particular to be used in the treatment of neurodegenerative diseases and Amyotrophic Lateral Sclerosis (ALS), and compositions comprising such synthetic peptide. Furthermore, the invention concerns processes for the preparation of said synthetic peptide.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: October 13, 2020
    Assignees: Dip. di Scienze Biomediche e Biotecnologiche, Dip.di Scienze Biologiche, Geologiche e Ambientali
    Inventors: Angela Anna Messina, Vito Nicola De Pinto, Andrea Magri′, Simona Reina, Francesca Maria Guarino
  • Patent number: 10772900
    Abstract: The invention includes a method of treating or preventing a Staphylococcus infection in a mammal or avian species in need thereof. The methods comprise administering to the mammal or avian species a therapeutically effective amount of fosmidomycin. In certain embodiments, the methods treat or prevent a drug-resistant Staphylococccus infection.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: September 15, 2020
    Assignee: The Trustees of The University of Pennsylvania
    Inventors: Daniel P. Beiting, Ana M. Misic, Shelly C. Rankin
  • Patent number: 10765697
    Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 8, 2020
    Assignee: L & F RESEARCH LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10743542
    Abstract: In one aspect, the present disclosure belongs to the new material field and can be used to produce atomic-state fluid iodine by iodine atom rearrangement occurring in the pseudo-critical reaction system. In one aspect, the atomic-state fluid iodine has a specific gravity of about 3.8-4.0 g/mL and maintains stable physical state under 10-100 C and light environment without sublimation or decomposition.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: August 18, 2020
    Assignee: CHINESE ACADEMY OF AGRICULTURAL ENGINEERING PLANNING & DESIGN
    Inventors: Shikui Wang, Xuefang Hu, Zhimin Zhang, Liang Liang, Zhiqing Tian
  • Patent number: 10736973
    Abstract: Provided are methods and formulations for imaging at least one body region of a subject, employing a glucose analog resistant or inactive to phosphrylation, or which is not a substrate for hexokinase.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: August 11, 2020
    Assignee: TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP
    Inventors: Gil Navon, Michal Rivlin, Ilan Tsarfaty
  • Patent number: 10721955
    Abstract: An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: July 28, 2020
    Assignee: International IP Holdings LLC
    Inventor: Manoj Bhargava
  • Patent number: 10717789
    Abstract: A polydisperse inulin product has a factor L, defined as a ratio S/D, wherein: S equals the sum of the compounds GF2, F3, and F4 in the inulin product, expressed in wt. % on total carbohydrates; D equals [(Fi/Gi)+1], wherein Fi is the amount of inulin-related fructose in the inulin product, Gi is the amount of inulin-related glucose in the inulin product, whereby Fi and Gi are expressed in wt. % on total carbohydrates, wherein the value of L lies between 2.0 and 3.0 and wherein between 3 and 20 wt. % on total carbohydrates of the inulin product is: GFn compounds wherein n is 10 or greater, and/or Fm compounds wherein m is 11 or greater.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: July 21, 2020
    Assignee: TIENSE SUIKERRAFFINADERIJ N.V.
    Inventor: Linda Mertens
  • Patent number: 10716802
    Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 21, 2020
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Jeffrey M. Karp, Yuhan Lee, Ali Tavakkoli, Tarawatie E. Deelman
  • Patent number: RE49080
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: May 24, 2022
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang